Mechanisms Regulating the Secretion of the Promalignancy Chemokine CCL5 by Breast Tumor Cells: CCL5's 40s Loop and Intracellular Glycosaminoglycans  by Soria, Gali et al.
Mechanisms Regulating the
Secretion of the Promalignancy
Chemokine CCL5 by Breast Tumor
Cells: CCL5’s 40s Loop and
Intracellular Glycosaminoglycans1,2
Gali Soria*, Yaeli Lebel-Haziv*,3, Marcelo Ehrlich*,3,
Tsipi Meshel*, Adva Suez†, Edward Avezov*,
Perri Rozenberg* and Adit Ben-Baruch*
*Department of Cell Research and Immunology, George S.
Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv,
Israel; †Bioinformatics Unit, George S. Wise Faculty of Life
Sciences, Tel Aviv University, Tel Aviv, Israel
Abstract
The chemokine CCL5 (RANTES) plays active promalignancy roles in breast malignancy. The secretion of CCL5 by
breast tumor cells is an important step in its tumor-promoting activities; therefore, inhibition of CCL5 secretion
may have antitumorigenic effects. We demonstrate that, in breast tumor cells, CCL5 secretion necessitated the
trafficking of CCL5-containing vesicles on microtubules from the endoplasmic reticulum (ER) to the post-Golgi stage,
and CCL5 release was regulated by the rigidity of the actin cytoskeleton. Focusing on the 40s loop of CCL5, we found
that the 43TRKN46 sequence of CCL5 was indispensable for its inclusion in motile vesicles, and for its secretion. The
TRKN-mutated chemokine reached the Golgi, but trafficked along the ER-to-post-Golgi route differently than the
wild-type (WT) chemokine. Based on the studies showing that the 40s loop of CCL5 mediates its binding to glyco-
saminoglycans (GAG), we analyzed the roles of GAG in regulating CCL5 secretion. TRKN-mutated CCL5 had lower
propensity for colocalization with GAG in the Golgi compared to the WT chemokine. Secretion of WT CCL5 was
significantly reduced in CHO mutant cells deficient in GAG synthesis, and the WT chemokine acquired an ER-like
distribution in these cells, similar to that of TRKN-mutated CCL5 in GAG-expressing cells. The release of WT CCL5
was also reduced after inhibition of GAG presence/synthesis by intracellular expression of heparanase, inhibition of
GAG sulfation, and sulfate deprivation. The need for a 43TRKN46 motif and for a GAG-mediated process in CCL5
secretion may enable the future design of modalities that prevent CCL5 release by breast tumor cells.
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Introduction
The inflammatory milieu plays a key role in regulating tumor growth
and progression [1–3]. A growing number of studies suggest that the
inflammatory CC chemokine CCL5 (also known as RANTES) has
major tumor-supporting activities in several cancer diseases [4,5].
CCL5 was extensively studied in breast cancer, where it was shown
to causatively promote malignancy [4,5]. The chemotactic properties
of CCL5 lead to elevated levels of deleterious tumor-associated macro-
phages in breast tumors, and it was suggested that this chemokine recruits
inflammatory TH17 cells to the tumor site [6–9]. In parallel, the chemo-
kine promotes the release of matrix-degrading enzymes by the tumor
cells [7,10] and induces their migration and invasion [10–19]. Particu-
larly, the chemokine was shown to promote the invasiveness of cells
having the CD44+/CD24− phenotype of tumor-initiating cells [19].
The importance of CCL5 in breast cancer is reinforced by the fact
that its inhibition has led to reduced malignancy in animal model
systems of breast cancer, indicating that the chemokine has a causative
role in promoting breast cancer [6,8,13,20–22]. In line with the above,
CCL5 was intimately linked with advanced and aggressive disease in
patients and with lymph node involvement and was suggested as a
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potential prognostic factor predicting progression in stage II breast
cancer patients [19,23–26].
In biopsies of breast cancer patients, the most important source for
CCL5 is the cancer cells themselves [5,9,19,23–30]. Recent studies
indicate that the expression of the procancerous chemokine CCL5 is
acquired in the course of malignant transformation, and its release by
the tumor cells enables its paracrine and autocrine activities on cells of
the tumor microenvironment and on the tumor cells, respectively
[4,5,19,27,31]. Therefore, the secretion of CCL5 by breast cancer cells
is a key regulatory step whose inhibition may lead to a significant re-
duction in the tumor-promoting activities induced by this chemokine.
The aim of the present study was to characterize the mechanisms
that control the secretion of CCL5 by breast tumor cells. Specifically,
we wished to identify chemokine domains that are required for CCL5
secretion and cellular components that regulate the release of this
chemokine by breast tumor cells. The findings of this study indicate
that the chemokine is mobilized in well-organized vesicles on micro-
tubules from the endoplasmic reticulum (ER) to the post-Golgi stage
and that its release by the tumor cells is an actin-regulated process.
Furthermore, by using a mutated CCL5, we have identified a four-
amino-acid motif in the 40s region of CCL5, 43TRKN46, that is
essential for its inclusion in motile vesicles and for its secretion by
breast cancer cells. We have also shown that glycosaminoglycans
(GAG) play an important regulatory role, although partial, in mediat-
ing CCL5 release by the tumor cells.
The above results indicate that the 43TRKN46 sequence of CCL5
and intracellular GAG are essential for the secretion of CCL5. When
these results are considered with additional findings provided in this
study, and in the literature, we suggest that one of the mechanisms that
mediate the secretion of CCL5 by breast tumor cells is based on the
association of the 40s loop of CCL5 with intracellular GAG that make
their way to the cell surface or to the cell exterior. The identification of a
43TRKN46-mediated and GAG-mediated process of CCL5 secretion
may set the basis for the future design of inhibitors that would re-
duce the secretion of CCL5 by breast tumor cells and thus may limit
CCL5-dependent processes that are involved in breast malignancy.
Materials and Methods
Cell Cultures
The MCF-7 and T47D human breast carcinoma cell lines were
grown in Dulbecco modified Eagle medium (DMEM) as described
previously [24]. MDA-MB-231 cells were cultured in DMEM as
above. MCF-10A cells were cultured in DMEM/F12 supplemented
with 5% horse serum, 10 μg/ml insulin, 20 ng/ml epidermal growth
factor (all purchased from Biological Industries, Beit Haemek, Israel),
100 ng/ml cholera toxin (Sigma-Aldrich, St Louis, MO), and 0.5 μg/ml
hydrocortisone (Sigma). WI-38 cells (kindly provided by Prof Rotter,
Weizmann Institute of Science, Rehovot, Israel) were cultured in min-
imum essential medium (Sigma) supplemented with 10% fetal calf
serum and 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 250 ng/ml amphotericin
(Biological Industries). Human mammary normal epithelial cells
(HMECs; kindly provided by Dr Berger, Sheba Medical Center,
Tel-Hashomer, Israel) were cultured in MEGM Ready Medium
(Lonza, Walkersville, MD). CHO-K1 and CHO-pgsA-745 cells
(kindly provided by Prof Vlodavsky, Technion, Haifa, Israel) were cul-
tured in DMEM and RPMI 1640medium, respectively, supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 100 U/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml
amphotericin (Biological Industries).
Before the different experimental procedures, the various cell lines were
transferred to their corresponding serum-free media, except for MCF-
10A cells that were transferred to LPM medium (Biological Industries).
Chemokine Sequences
The vector used in most analyses in this study was pEGFP-N1, ex-
pressing WT or 43TRKN46-mutated CCL5 (Table 1). The constructs
of WT and mutated CCL5 were produced by polymerase chain re-
action, and the sequences of both chemokines were validated by
full-length sequencing. In parallel, we used the pcDNA3.1-zeo(−)
vector, expressing HA-tagged WT CCL5, whose sequence was vali-
dated by full-length sequencing.
Bioinformatics Analysis of Chemokine Structure
Models were built using Rosetta 3.1 AbinitioRelax protocol, with
protein structure prediction using Rosetta [32]. The sequence of the
TRKN-mutated CCL5 [named CCL5(TRKN–)], SPYSSDTTPCC-
FAYIARPLPRAHIKEYFYTSGKCSNPAVVFVAAAARQVCAN-
PEKKWVREYINSLEMS, was superimposed on the x-ray structure
of WT CCL5 (PDB 1U4M [33]; the modeling started at amino acid
14 because the mutated chemokine was modeled as monomer, whereas
the x-ray structure of WT CCL5 was of a dimer, in which the N′ is
differently organized compared to the monomer). To predict the ap-
propriate folding of the mutated CCL5 protein, an ab initio protocol
was applied, which predicts the structure of a protein based on its se-
quence. The final model presented was chosen out of 10,000 decoys,
based on their lowest score. The model was further assessed using
the MolProbity Web server [34], which examines psi and phi angles,
C-beta deviations, atom clashes, and rotamers.
Transfection and Determination of Transfection Yields
MCF-7 and T47D cells were transfected by electroporation as de-
scribed previously [35]. The other cell types were transfected by ICA
Fectin 441 DNA transfection reagent (MedProbe, Oslo, Norway)
according to the manufacturer’s instructions.
Transfection outcome was evaluated by flow cytometry analyses
(fluorescence-activated cell sorter [FACS]). The cells were washed with
phosphate-buffered saline supplemented with 0.02% sodium azide,
and the expression of GFP was determined with a Becton Dickinson
FACSort (Mountain View, CA) using the CellQuest software.
Determination of CCL5 Secretion by ELISA
The different cell types were grown in serum-free medium for 24 to
48 hours. In specific cases, the cells were treated by brefeldin A (BFA;
Sigma; in two experiments, we used 5 μg/ml BFA for 2 hours, and in
one additional experiment, we used 25 μg/ml for 5 hours; the two con-
ditions yielded similar results), by latrunculin (5 μg/ml; Sigma), or
Table 1. Sequences of GFP-CCL5(WT) and GFP-CCL5(TRKN–) Used in the Study.





The sequences of the GFP-CCL5(WT) and GFP-CCL5(TRKN–) are presented starting at their
34th amino acid. The sequence that was mutated to alanines (43TRKN46) is underlined.
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by jasplakinolide [10−6 M; Alexis, Farmingdale, NY]) for 2 hours at
37°C. In other cases, the cells were treated by BFA for 20 minutes at
room temperature.When the cells were treated by nocodazole (15 μg/ml;
Sigma), they were incubated as follows: 15 minutes at 4°C without the
drug; 15 minutes at 4°C with the drug; 1.5 hours at 37°C with the drug.
Treatment with sodium chlorate (30 mM; Sigma) was performed for
48 hours at 37°C. In all cases, control treatments included incubation
of the cells with the relevant diluents of the reagents for similar periods.
The inhibitors did not affect cell viability.
When sulfate deprivation was induced, the cells were grown for
48 hours with magnesium sulfate–deprived medium (Biological Indus-
tries; to replenish the magnesium, a similar quantity of magnesium
chloride was added to the medium). Control cells were grown with
regular DMEM.
In other experiments, MCF-7 cells were transiently or stably trans-
fected with a myc-tagged pSecTag vector-expressing heparanase or with
an empty vector as control (kindly provided by Prof I. Vlodavsky,
Technion, Haifa, Israel). In parallel, the cells were transiently trans-
fected with GFP-CCL5(WT).
Chemokine levels in cell supernatants were determined by ELISA,
using standard curves with recombinant human CCL5 at the linear
range of absorbance. The ELISA analyses were performed in the
following manners: Procedure 1. Unless otherwise indicated, the ELISA
studies were performed with antibodies against CCL5: coating—mouse
monoclonal antibodies (mAbs) against human CCL5 (PeproTech,
Rocky Hill, NJ); detection—biotinylated polyclonal goat anti-human
CCL5 antibodies (R&D Systems, Minneapolis, MN). Procedure 2.
Coating—mouse mAb against GFP (Covance, Princeton, NJ; MBL
International, Woburn, MA); detection—biotinylated polyclonal rab-
bit anti-GFP antibodies (Sigma). Procedure 3. Coating—mouse mAb
against GFP (Covance); detection—biotinylated polyclonal goat
anti-human CCL5 antibodies (PeproTech). Procedure 4. Coating—
polyclonal rabbit antibodies against human CCL5 (PeproTech);
detection—biotinylated polyclonal goat anti-human CCL5 antibodies
(PeproTech). P values were calculated by Student’s t test.
Determination of CCL5 Expression by Western Blot Analysis
MCF-7 cells were transiently transfected with vectors expressing
GFP-CCL5(WT), GFP-CCL5(TRKN–) or GFP only. The proteins
were immunoprecipitated from cell lysates by mouse mAb against
GFP (Covance), and Western blot for GFP was performed by mouse
mAb against GFP (Covance).
Confocal Analyses
Cells transiently transfected with vectors expressingGFP-CCL5(WT),
GFP-CCL5(TRKN–), GFP only, or HA-CCL5(WT) were grown in
growth medium on coverslips for 24 hours and then in serum-free me-
dium for another 24 hours at 37°C. Actin polymerization was detected
by phalloidin (40 minutes; Molecular Probes, PoortGebouw, the
Netherlands) after cell fixation and permeabilization [36].
To determine the localization of CCL5 in the ER, staining was
performed with rabbit antibodies against calnexin (Sigma), then
with DyLight 549–conjugated AffiniPure goat anti-rabbit antibodies
( Jackson Immunoresearch Laboratories, West Grove, PA). To de-
termine the localization of CCL5 in the Golgi, a vector expressing
the Golgi marker α mannosidase IB, tagged by HA, was expressed
by transfection in the cells. HA was detected by rabbit antibodies
against HA (Santa Cruz Biotechnology, Santa Cruz, CA), then stained
by DyLight 549–conjugated AffiniPure goat anti-rabbit antibodies
(Jackson Immunoresearch Laboratories). Negative controls included
cell staining by secondary antibodies only, as well as by an isotype-
matched nonrelevant antibody (data not shown). In this set of ex-
periments, stained cells were imaged by Zeiss LSM-510 confocal
microscope (Zeiss, Thornwood, NY). Determination of colocalization
of GFP-CCL5(WT) or GFP-CCL5(TRKN–) with markers of the ER
or of the Golgi was performed by Slidebook software (Slidebook,
Denver, CO), applied on a large number of cells.
In parallel, experiments were performed to determine the colocaliza-
tion of GFP-CCL5(WT) or GFP-CCL5(TRKN–) with GAG in the
Golgi. In these experiments, MCF-7 cells were transiently transfected
by constructs expressing GFP-CCL5(WT) or GFP-CCL5(TRKN–)
and simultaneously with the Golgi marker α mannosidase IB, tagged
by HA. The cells were stained with Texas Red–labeled Lycopersicon
Esculentum (Tomato) Lectin (Vector Laboratories, Burlingame, CA)
and with rabbit antibodies against HA (Santa Cruz), followed by Alexa
Fluor 647 goat anti-rabbit IgG (H + L) highly cross-adsorbed anti-
bodies (Invitrogen, Carlsbad, CA). Stained cells were imaged with
Zeiss LSM-510 confocal microscope and with spinning disk confocal
microscope, carried out with Axiovert 200M microscope (Zeiss) cou-
pled to a Yokogawa CSU-22 spinning disk confocal head (Yokogawa,
Sugar Land, TX). Slidebook software was used for determination of
colocalization of GFP-CCL5(WT) or GFP-CCL5(TRKN–) with
GAG in the Golgi.
In additional experiments, HA-CCL5(WT) was detected in the
cells, stained by antibodies against HA (as above), and then with
DyLight 549–conjugated AffiniPure goat anti-rabbit IgG (Jackson
Immunoresearch Laboratories). Analysis was performed with Zeiss
LSM-510 confocal microscopy, as above.
Live Cell Imaging
MCF-7 cells were transiently transfected by vectors expressing GFP-
CCL5(WT) or GFP-CCL5(TRKN–) and, 48 hours later, were imaged
by live cell spinning disk confocal microscopy. Two-dimensional time-
lapse series were acquired with a 3-second interval. To visualize the
paths taken by moving vesicles containing GFP-CCL5(WT), images
were projected in two dimensions using the maximum-value-per-pixel
algorithm of Slidebook. The two dimensional algorithm was pseudo-
colored in red and expanded through the entire time-lapse series.
Results
Vesicles Containing CCL5 Are Shuttled from the ER to
the Post-Golgi Stage, Leading to CCL5 Secretion by
Breast Tumor Cells
In the present study, we wished to identify CCL5 domains and intra-
cellular components regulating the secretion of the chemokine by breast
tumor cells and to detect intracellular regulatory determinants of CCL5
secretion. To this end, we have expressed in the tumor cells GFP-tagged
human wild-type (WT) CCL5, namely GFP-CCL5(WT). At first, we
wished to guarantee that the GFP-tagged CCL5 acts in similar manners
to those characterized for endogenous CCL5 that is constitutively pro-
duced by the same tumor cells [27] and to further extend our understand-
ing of basic mechanisms involved in CCL5 secretion by the tumor cells.
Being a secretory protein expressing a signal peptide, we have shown
in our published study that endogenous CCL5 is organized in vesicles
in MCF-7 breast tumor cells and is secreted by breast tumor cells in an
ER-to-Golgi–dependent process [27]. In the present study, we show
similar characteristics for the GFP-tagged CCL5 that we have produced,
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analyzed in MCF-7 cells (Figures 1 and 2). The results in Figure 1A
demonstrate that the GFP-tagged chemokine had a pronounced vesicular
organization, with high propensity to Golgi localization, as was con-
firmed in colocalization analyses described below. This pattern of intra-
cellular localization also applied to CCL5 labeled by a smaller tag, when
we used HA-tagged CCL5(WT), showing vesicular organization and
distribution typical of Golgi (Figure W1).
Using the GFP-tagged CCL5 in our further analyses, we found that
CCL5-containing vesicles had a very dynamic motility in the cells
(Video W1). As expected, owing to the transfection with GFP-CCL5
(WT) (Figure 1B1), high levels of the chemokine were detected in the
supernatants of the cells (Figure 1B2). The transfection of the cells by
GFP-tagged empty vector (named GFP) allowed us to determine the
background levels of endogenous CCL5 released by the cells. In most
analyses included in the study (see below), it was difficult to detect
the endogenous chemokine after transfection of the cells by GFP (as
is the case in Figure 1B2). Please note that the MCF-7 cells used in this
analysis, before their transfection by vector expressing GFP-CCL5
(WT), release endogenous CCL5 [24,27,31], but in lower levels than
the nanogram amounts released after the expression of the transfected
WT chemokine. Therefore, the endogenous CCL5 is hardly detected
under the current experimental conditions, designed to provide reliable
detection curves of high nanogram CCL5 levels.
After these analyses that have verified the secretion of the GFP-
tagged CCL5, we asked if the chemokine is released by the tumor cells
in an ER-to-Golgi–dependent process, as was shown to be the case in
our previous study of endogenous CCL5 in breast tumor cells. In that
published investigation [27], we have shown that BFA, a drug that
induces the collapse of the Golgi apparatus and blocks the transport
of proteins from the ER to the trans-Golgi network [37,38], has led to
a pronounced inhibition of secretion of endogenous CCL5 by the
tumor cells. In line with those findings on the endogenous chemokine,
when GFP-CCL5(WT)–transfected tumor cells were treated with
BFA (2-5 hours; see Materials and Methods), GFP-CCL5(WT)
Figure 1. CCL5 is organized in vesicles and is secreted by breast tumor cells. Human MCF-7 breast tumor cells were transiently trans-
fected by a vector expressing GFP-CCL5(WT) or by a control vector expressing GFP only (=GFP). (A) GFP-CCL5(WT) acquires a vesicular
distribution in the tumor cells, as determined by confocal analysis (similar localization pattern was observed for HA-tagged WT CCL5, as
shown in Figure W1). This vesicular distribution is similar to that of endogenous CCL5 produced by the cells [27]. Live cell imaging of
motility of GFP-CCL5(WT)–containing vesicles is demonstrated in Video W1. The control empty vector expressing GFP had a diffuse
nonorganized distribution in the cells (data not shown). (B) Determination of transfection yields and of CCL5 secretion by MCF-7 cells
transfected with the GFP-CCL5(WT) vector and by the control GFP vector. (B1) Transfection yields based on GFP expression in FACS
analysis. (B2) CCL5 secretion to the cell supernatants, determined by ELISA assays with antibodies against human CCL5, as described in
procedure 1 in Materials and Methods. In each part of the figure, the results are representatives of at least n = 3.
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assumed a reticulate pattern with an enhanced localization to the
nuclear membrane, typical of ER localization (Figure 2A1), and almost
complete inhibition of CCL5 secretion was obtained (Figure 2A2).
This observation indicated that the secretion of the GFP-tagged
CCL5 that we have produced, similarly to that of the endogenous
CCL5 [27], requires ER-to-Golgi trafficking.
Also, in our published study, we have shown that endogenously ex-
pressed CCL5 is secreted from premade vesicles, localized to the cell
periphery [27]. To confirm the presence of such a secretion-ready
vesicle population and to extend our understanding of the mechanisms
involved in CCL5 secretion, we used a relatively short BFA treatment
(20 minutes) designed to induce the collapse of the Golgi without
affecting the vesicle population that has already reached the post-Golgi
stage close to the cell periphery. Video W2, provided as static pictures
in Figure 2, B1 and B2, shows by live cell imaging that despite the
collapse of the Golgi, CCL5 was still localized to motile vesicles, in
accord with its localization to a post-Golgi secretory compartment
adjacent to the cell membrane.
Overall, the above findings validate the suitability of the GFP-tagged
CCL5 for further research and are in line with our published results
[27]. In addition, these results provide additional insights into basic
events taking place in the course of CCL5 secretion, showing that
CCL5-containing vesicles mobilize in a dynamic manner from the
ER to the post-Golgi stage and give rise to a productive process of
CCL5 secretion to the cell exterior.
Vesicles Containing CCL5 Move on Structured Microtubule
Tracks, and the Release of the Chemokine Is Regulated by
the Rigidity of the Actin Cytoskeleton
The observations obtained in the previous part of the study demon-
strated a dynamic behavior of vesicles containing GFP-CCL5(WT),
along well-structured paths in the cells (Video W1). To envision the
tracks undertaken by the vesicles and to understand if the same
paths were reused over time, we projected and pseudocolored in red
the maximum intensity of the GFP signal of individual frames and
superimposed this signal on the original time-lapse series. Video W3,
Figure 2. Vesicles containing CCL5 are shuttled from the ER to the post-Golgi stage. The effects of treatment by BFA on the intracellular
organization of vesicles containing GFP-CCL5(WT) and on CCL5 secretion. Control cells were treated by the solubilizer of the drug. (A)
Human MCF-7 breast tumor cells were transiently transfected by a vector expressing GFP-CCL5(WT), and the pool of cells was split to
cells treated by BFA or to control cells treated by the solubilizer of the drug. The drug did not affect cell viability (data not shown). (A1)
Confocal analysis showing cells treated by BFA for 2 hours. Before BFA addition, the localization of GFP-CCL5(WT) was as in Figure 1A
(vesicular and punctuate; data not shown). The picture is a representative of multiple cells analyzed in n = 2. (B) ELISA analysis of CCL5
amounts in supernatants of cells untreated or treated by BFA (for 2-5 hours, as described in Materials and Methods). The results are
similar to those obtained for the endogenous CCL5 produced by breast tumor cells, shown to be mobilized toward secretion in an ER-to-
Golgi–dependent manner [27]. CCL5 secretion to the cell supernatants was determined by ELISA assays with antibodies against human
CCL5, as described in procedure 1 in Materials and Methods. (B) The effect of short-term treatment by BFA (20 minutes) on motility of
CCL5-containing vesicles. Human MCF-7 cells were transiently transfected by GFP-CCL5(WT), and the motility of CCL5-containing
vesicles was determined by live cell imaging in spinning disk confocal microscope after the treatment by BFA. The figure provides static
pictures of Video W2. (B1) At the beginning of the BFA treatment, prominent localization of CCL5 was detected in the Golgi, and the
chemokine was also found in peripheral vesicles. (B2) At advanced stages after this short treatment by BFA, there was almost an entire
collapse of the Golgi, CCL5 was minimally detected in the Golgi, but it was still vastly localized in peripheral vesicles. The pictures are
representatives of multiple cells analyzed in n ≥ 2.
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provided as a static picture in Figure 3A, clearly shows that the vesicles
containing GFP-CCL5(WT) (yellow, owing to the superimposition of
the red signal of the tracks and the green signal of GFP-CCL5(WT))
traffic along structured, defined, and extended routes, which stretch
throughout the cells (shown in red).
Because vesicles containing GFP-CCL5(WT) had apparent
directional motility and they reused defined paths, we tested the
possibility that vesicles carrying the chemokine move along cyto-
skeleton filaments. Depolymerization of microtubules by nocoda-
zole [39] reduced considerably the motility of CCL5-containing
vesicles, and decelerated their movement along well-defined paths
(Video W4: before nocodazole treatment; Video W5: after nocodazole
treatment). In parallel, depolymerization of the microtubules sig-
nificantly inhibited CCL5 secretion by the tumor cells (Figure 3B),
Figure 3. The trafficking and secretion of CCL5 are regulated by cytoskeleton elements. The characteristics of CCL5 trafficking and secretion
were determined in human MCF-7 breast tumor cells, transiently transfected by a vector expressing GFP-CCL5(WT). (A) GFP-CCL5(WT)–
containing vesicles traffic on structured cellular tracks. The cells were imaged by live cell imaging in confocal microscopy. The figure shows
a static picture of Video W3. To visualize the paths taken by moving GFP-CCL5(WT)–containing vesicles, images were projected in two
dimensions using the maximum-value-per-pixel algorithm of Slidebook. The two-dimensonal algorithm was pseudocolored in red and
expended through the entire time-lapse series. The tracks used by GFP-CCL5(WT)–containing vesicles are demonstrated in red, and the
vesicles containing GFP-CCL5(WT) (green) are shown in yellow, owing to the superimposition of red and green signals. The pictures are
representatives ofmultiple cells analyzed in n=2. (B, C, D) The roles ofmicrotubules (B) and of actin filaments (C, D) in regulating themotility
of CCL5-containing vesicles and the secretion of CCL5were determined in MCF-7 cells. After transient transfection with a vector expressing
GFP-CCL5(WT), the pool of cells was split to cells treated with (B) nocodazole (microtubule depolymerizing), (C) latrunculin (actin depoly-
merizing), or (D) jasplakinolide (actin polymerizing) and to control cells that were treated by the solubilizers of the drugs. The drugs did not
affect cell viability (data not shown). (B) CCL5 secretion after treatment by nocodazole was determined as indicated below. In parallel,
the motility of vesicles containing GFP-CCL5(WT) was followed by live cell imaging in confocal microscopy, without (Video W4) and follow-
ing nocodazole treatment (Video W5). (C) The effects of latrunculin on the organization of actin filaments were determined by staining con-
trol cells (C1) or latrunculin-treated cells (C2) with phalloidin. (C3) CCL5 secretion after latrunculin treatment was determined as indicated
below. (D) The effects of jasplakinolide on the shape and contour of the cells were determined by light microscope in control cells (D1) and in
jasplakinolide-treated cells (D2). (D3) CCL5 secretion after jasplakinolide treatment was determined as indicated below. (B, C3, D3) CCL5
secretion to the cell supernatants was determined by ELISA analyses with antibodies against human CCL5, as described in procedure 1 in
the Materials and Methods. In all parts of the figure, the ELISA analyses are of a representative experiment of n = 3, and the pictures are
representatives of multiple cells analyzed in n = 3 (except for the live cell imaging in B, where n = 2).
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being in line with the above findings showing that the inclusion of
CCL5 into motile vesicles is important for its secretion (Video W1
and Figure 2).
In addition, we have analyzed the roles of the actin cytoskeleton in
regulating the secretion of CCL5 by the tumor cells. After depolymeri-
zation of the actin filaments by latrunculin [40] (Figure 3, C1 and C2),
the secretion of CCL5 was promoted (Figure 3C3), suggesting that the
membrane-proximal actin cortex acts as a partial barrier that prevents
maximal vesicle fusion and secretion of the chemokine. This possibility
was supported by taking the opposite approach, in which the cells were
treated by the actin polymerizing agent jasplakinolide [41]. This drug
has led to change in cell shape and contour that are consistent with
increased rigidity of the actin cortex (Figure 3, D1 and D2) and inhib-
ited the secretion of CCL5 by the tumor cells (Figure 3D3).
Together, the above observations indicate that microtubules serve
as structured tracks along which the chemokine-containing vesicles
shuttle toward secretion, whereas the actin cytoskeleton controls
the extent of chemokine release to the extracellular milieu of the cells.
The 43TRKN46 Sequence of CCL5 Is Essential for Its Secretion
by Breast Tumor Cells and for Its Inclusion in Motile Vesicles
Next, we asked what are the chemokine motifs that are essential for
its release by breast tumor cells and chose to focus on the 43TRKN46
sequence located in the 40s loop of CCL5. The rationale for focusing
on this motif was based on the following two observations: 1) A recent
study by El Golli et al. [42] has shown that the 45LKNG48 sequence
of CXCL4 facilitates the targeting of this chemokine to granules in
platelets. That research has suggested that the 45LKNG48 sequence
of CXCL4 exhibits the same surface-exposed hydrophilic turn/loop
features as the 43TRKN46 sequence of CCL5, thus motivating us to
ask whether the 43TRKN46 sequence of CCL5 regulates its secretion
by breast tumor cells. 2) The 43TRKN46 sequence is found in the
exposed 40s loop of CCL5, known to be important for CCL5 binding
to GAG and to the CCL5 receptors CCR1 and CCR3 [33,43,44].
Therefore, we speculated that such a region may mediate the inter-
actions of the chemokine with intracellular components that shuttle
it toward secretion.
On the basis of the above, we asked if the 43TRKN46 motif of CCL5
is required for the secretion of the chemokine by breast tumor cells.
To this end, we generated a CCL5(TRKN–) variant in which the
43TRKN46 motif was mutated to alanines. To guarantee that the
TRKN-mutated chemokine is correctly folded, we have performed
the following two analyses: 1) We determined the predicted three-
dimensional structure of the TRKN-mutated chemokine by super-
imposing it on the x-ray structure of WT CCL5 [33]. This analysis
has shown that the TRKN-mutated CCL5 is correctly folded (Fig-
ure 4A), and this conclusion is supported by past studies showing that
CCL5 mutated at 44RKNR47 (a sequence shifted one amino acid from
our 43TRKN46 motif ) had similar x-ray characteristics to WT CCL5
[33]. 2) Further below in the article, we describe studies determining
the intracellular localization of GFP-CCL5(WT) and GFP-CCL5
(TRKN–). In those experiments (see below), we found that the mu-
tated CCL5 exited from the ER to the Golgi, a process that could
not have taken place if the mutated chemokine was misfolded owing
to ER-associated protein degradation (ERAD) that ensures that only
properly folded and assembled proteins proceed to the Golgi for further
processing and secretion [45–47].
We now asked if the vectors expressing GFP-CCL5(WT) and GFP-
CCL5(TRKN–) generate proteins at the correct molecular weights
(MWs). Western blot analyses performed on cell lysates of cells trans-
fected with GFP-CCL5(WT) and with GFP-CCL5(TRKN–) have
shown that the two proteins had a similar MW, and they both assumed
the expected MW of 35 kDa, as expected for CCL5 tagged by GFP
(CCL5, ∼8 kDa; GFP, ∼27 kDa) (Figure 4B).
After these analyses, we have determined the secretion of GFP-CCL5
(WT) and GFP-CCL5(TRKN–) by the tumor cells. Figure 4C shows
that the transfection yields of GFP-CCL5(TRKN–) were very similar
to those of GFP-CCL5(WT) in the tumor cells. However, whereas
the WT chemokine was highly secreted and was detected in high levels
in the cell supernatants, very substantial inhibition of secretion was
obtained for the mutated GFP-CCL5(TRKN–) (Figure 4, D1 and
D2). This was indicated by ELISAs performed with antibodies against
CCL5 (Figure 4D1) and with antibodies against the GFP tag
(Figure 4D2). Very prominent reduction in the secretion of the GFP-
CCL5(TRKN–) was obtained also by two additional ELISA analyses
performed with other combinations of antibodies (Figure W2).
In line with the perturbed secretion of the mutated GFP-
CCL5(TRKN–) by the tumor cells, we found that the mutated chemo-
kine had a diffuse/reticulate distribution, with no definite vesicular
organization (Figures 5 and 6). Live cell imaging experiments have shown
that the motility of the mutated chemokine was limited, random, and
nondirectional (Video W6), in contrast to the dynamic and directional
motility of vesicles containing GFP-CCL5(WT) (Video W1). These
findings, showing lack of vesicular localization ofGFP-CCL5(TRKN–),
support fully the prominent reduction observed in secretion of the
mutated chemokine by the tumor cells.
The TRKN-Mutated Chemokine Reaches the Golgi, but
Traffics along the ER-to-Post-Golgi Route in a Different
Manner than the WT Chemokine
The above results indicate that the 43TRKN46 motif of CCL5 is
essential for the vesicular organization and for the secretion of the
chemokine by breast tumor cells. To provide further insights to
the mechanisms responsible for reduced secretion of the TRKN-
mutated CCL5, we have determined its intracellular localization
along the ER-to-Golgi trafficking process, relative to the WT che-
mokine. To this end, we studied the colocalization of the WT
CCL5 or mutated CCL5 chemokines with markers of the ER
(calnexin) and of the Golgi (α mannosidase IB). The extent of
colocalization was also determined quantitatively, as described in
Materials and Methods.
The results in Figures 5 and 6 indicate that the GFP-CCL5
(TRKN–) exited from the ER to the Golgi, however, with modified
proportions compared to the WT chemokine. The TRKN-mutated
chemokine had higher propensity for ER localization than the WT
chemokine (Figure 5), and in parallel, its expression in the Golgi was
somewhat reduced (Figure 6). These results indicate that: 1) The
43TRKN46 motif regulates the trafficking of CCL5 at two points along
the mobilization process, where the first stage takes place at the exit
from the ER to the trans-Golgi network and the second is in trafficking
of CCL5, in motile vesicles at the post-Golgi stage, a stage that is
required for completion of secretion. These findings agree well with
the reduced secretion of the TRKN-mutated CCL5 by the tumor cells.
2) GFP-CCL5(TRKN–) exited from the ER and reached the Golgi,
indicating that it is correctly folded because its inappropriate folding
would have led to activation of the ERAD process [45–47] that would
have completely prevented its exit from the ER.
Neoplasia Vol. 14, No. 1, 2012 Regulation of CCL5 Secretion in Breast Cancer Soria et al. 7
The 43TRKN46 Sequence Is a Ubiquitous Motif Required for
Secretion of CCL5 in Many Different Cell Types
In our search for the mechanisms that may be involved in the
43TRKN46-mediated process of CCL5 secretion, we first asked if the
dependence on the 43TRKN46 motif is a general phenomenon shared
by many cell types or whether it is specific to breast tumor cells in gen-
eral, or to MCF-7 cells in particular. To answer this question, we have
expressed GFP-CCL5(WT) and GFP-CCL5(TRKN–), which were
compared with control GFP vector, in several cell types. In each of
the cell types, we validated that the expression levels of GFP-CCL5
Figure 4. The 43TRKN46 motif of CCL5 is essential for its secretion by breast tumor cells. (A) The predicted three-dimensional structure
of 43TRKN46-mutated CCL5, superimposed on the three-dimensional structure of WT CCL5 obtained by x-ray analyses [33]. Of note,
this article also showed similar x-ray structures for WT CCL5 and the 44RKNR47 CCL5 mutant. (B) Human MCF-7 breast tumor cells
were transiently transfected by vectors expressing GFP-CCL5(WT), GFP-CCL5(TRKN–), or GFP alone (GFP), followed by determination
of chemokine expression in cell lysates. The chemokines were immunoprecipitated by mAb against GFP, and Western blot analysis was
performed with mAb against GFP. The results are of a representative experiment of n > 3. (C, D) The effects of the 43TRKN46 mutation
on CCL5 secretion. Human MCF-7 breast tumor cells were transiently transfected by vectors expressing GFP-CCL5(WT) or GFP-CCL5
(TRKN–), followed by determination of chemokine secretion. (C) FACS analyses showing the transfection yields of vectors expressing
GFP-CCL5(WT) or GFP-CCL5(TRKN–). (D) Determination of CCL5 secretion to cell supernatants, performed by ELISA assays. (D1) ELISA
assays with antibodies against human CCL5, as described in procedure 1 in Materials and Methods. (D2) ELISA assays with antibodies
against human GFP, as described in procedure 2 in Materials and Methods. The results in all parts of the figure are of a representative
experiment of n > 3. Additional ELISA analyses with other combinations of antibodies, showing the reduced secretion of GFP-CCL5
(TRKN–), are provided in Figure W2.
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(WT) were similar to those of GFP-CCL5(TRKN–) (Figure 7, A1-D1)
and determined the release of the WT or the mutated CCL5 by the cells
(Figure 7, A2-D2; please note that the levels of chemokines are presented
in different scales in the various panels of the figure).
We began this analysis by studying the T47D human breast tumor
cells that, like MCF-7 cells are tumorigenic but not metastatic, and the
MDA-MB-231 cells that are highly metastatic human breast tumor
cells [35]. In both cell types, the patterns of CCL5 release were similar
to those of MCF-7 cells: GFP-CCL5(WT) was highly secreted, whereas
the release of mutated CCL5 was prominently inhibited by the muta-
tion of the 43TRKN46 motif (Figure 7, A2 and B2). This has indicated
that the 43TRKN46 motif is involved in CCL5 trafficking in breast
tumor cells, independently of their metastatic potential.
We then asked if the same is correct for nontransformed human cells
of the breast (HMEC) and for normal human lung fibroblasts (WI-38)
(Figure 7, C2 and D2). We found that also in these two cell types, the
secretion of the mutated GFP-CCL5(TRKN–) chemokine was much
reduced when compared with the release of GFP-CCL5(WT) by
the cells. In general, reduced secretion of GFP-CCL5(TRKN–) was
also detected in the MCF-10A nontransformed breast epithelial cells
(data are not presented because, in several of the experiments, the
transfection procedure has led to very high release of endogenous
CCL5 by the cells, making the expression of GFP-CCL5(WT) ineffi-
cient. In these specific cases, it was difficult to interpret the exact pattern
of secretion of the mutated chemokine and to correctly appreciate what
seemed to be a dominant negative effect induced by GFP-CCL5
(TRKN–)).
Taken together, the above results indicate that the 43TRKN46-
dependent mechanism of CCL5 secretion is shared by many cell types
and is probably ubiquitous. These observations have led us to search
for a general mechanism, by which the 43TRKN46 motif is required
for the secretion of CCL5.
Figure 5. GFP-CCL5(TRKN–) is found in the ER in higher propensity than GFP-CCL5(WT). Confocal pictures showing the localization pat-
tern of GFP-CCL5(WT) and of GFP-CCL5(TRKN–) with the ER marker calnexin. (A) Human MCF-7 breast tumor cells were transiently trans-
fected by vectors expressing GFP-CCL5(WT) or GFP-CCL5(TRKN–). The colocalization of CCL5 (green) with an ER marker (calnexin, red)
was determined by confocal analysis and shown in orange/yellow. The pictures also show that, in contrast to the vesicular organization of
GFP-CCL5(WT), the GFP-CCL5(TRKN–) had a diffuse/reticulate organization. The nondirectional and limited motility of GFP-CCL5(TRKN–)
in the tumor cells is shown in Video W6. The pictures are representatives of multiple cells analyzed in n > 3. (B) Quantitative analysis of
the colocalization of the mutated and GFP-CCL5(WT) molecules with calnexin, performed on a large number of cells. The graph shows
the mean ± SD of the normalized values obtained in n = 3. P values were obtained from actual values of the computational analysis
before normalization.
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The Process of CCL5 Secretion Is Partly Regulated by GAG
In search for a general mechanism which leads to CCL5 secretion
and is shared by many cell types, we investigated the possibility that
CCL5 interacts with intracellular GAG on its trafficking route toward
release from the cells. This approach was based on published studies
showing that GAG-decorated proteoglycans participate in the packag-
ing of positively charged proteins in cytotoxic lymphocytes—such as
granzymes and perforin [48,49]—and that supernatants of activated
human immunodeficiency virus 1–specific cytotoxic T cells include
CC chemokines complexed with proteoglycans [50]. The latter study
did not address the involvement of GAG in the intracellular mobiliza-
tion of the chemokines toward secretion, but it motivated us to de-
termine the possibility that GAG regulate the intracellular trafficking
and release of the CC chemokine CCL5 in breast tumor cells. This
possibility was reinforced by the fact that the CCL5-secretory motif
of 43TRKN46 is only one amino acid shifted from the 44RKNR47 se-
quence of CCL5, known to be essential for CCL5 binding to GAG
[33,43,44]. Importantly, both 43TRKN46 and 44RKNR47 express posi-
tively charged amino acids that are part of the sequence required for
GAG binding [33,43,44]. Therefore, if indeed intracellular GAG are
required for CCL5 secretion, it is possible that they interact with the
43TRKN46 motif of CCL5, which is essential for the release of this
chemokine by the tumor cells.
On the basis of the above, our primary goal in this part of the study
was to determine whether the secretion of CCL5 by breast tumor
cells was regulated by intracellular GAG. To achieve this aim, we took
several approaches in which we determined the effects of GAG inhibi-
tion on the secretion of WT CCL5. In the framework of this study,
we have also addressed indirectly the possibility that the 43TRKN46
motif associates with such intracellular GAG. This point was not
addressed by direct measures because of two restrictions: 1) We found
that, because of technical reasons, it is impossible to isolate from
the transfected cells the actual molecules of GFP-CCL5(WT) and of
GFP-CCL5(TRKN–) in a manner that will enable determination of their
Figure 6. GFP-CCL5(TRKN–) reaches the Golgi apparatus but in a lower propensity than GFP-CCL5(WT). Confocal pictures showing the
localization pattern of GFP-CCL5(WT) and of GFP-CCL5(TRKN–) with the Golgi marker αmannosidase IB. (A) Human MCF-7 breast tumor
cells were transiently transfected by vectors expressing GFP-CCL5(WT) or GFP-CCL5(TRKN–). The colocalization of CCL5 (green) with a
Golgi marker (α mannosidase IB, red) was determined by confocal analysis and is shown in orange/yellow. The pictures also show that,
in contrast to the vesicular organization of GFP-CCL5(WT), the GFP-CCL5(TRKN–) had a diffuse/reticulate organization. The nondirectional
and limited motility of GFP-CCL5(TRKN–) in the tumor cells is shown in Video W6. The pictures are representatives of multiple cells
analyzed in n > 3. (B) Quantitative analysis of the colocalization of the mutated and GFP-CCL5(WT) molecules with α mannosidase IB,
performed on a large number of cells. The graph shows the mean ± SD of the normalized values obtained in n = 3. P values were
obtained from actual values of the computational analysis before normalization.
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binding to GAG on solid surfaces (plates or beads). 2) The approach of
CCL5 immunoprecipitation with GAGwas expected to be problematic
owing to the weak nature of the chemical bonds between them.
Below we provide data on the analyses that we have performed to
address the roles of intracellular GAG in CCL5 secretion and the
measures taken to address the possible involvement of the CCL5
43TRKN46 sequence in such a GAG-mediated process. The findings
provided below indicate that intracellular GAG are indeed involved
in CCL5 secretion. In parallel, our findings are suggestive of a process
in which the 43TRKN46 motif of CCL5 participates in a mechanism
mediated by GAG, and this possibility is supported by additional
findings in the literature, as detailed in the Discussion section.
Figure 7. The 43TRKN46 sequence is required for CCL5 secretion in many cell types. Different cell types were transiently transfected by
vectors expressing GFP-CCL5(WT), GFP-CCL5(TRKN–), or GFP alone (GFP) (please note the different scales used for the various cell types
in the ELISA analyses presented). (A1-D1) FACS analyses showing the transfection yields of GFP-CCL5(WT) and GFP-CCL5(TRKN–) in the
different cell types. (A2-D2) The secretion of CCL5 was determined by ELISA assays, performed on cell supernatants of the different cell
types, with antibodies against human CCL5, as described in procedure 1 in the Materials and Methods. (A1, A2) Human T47D nonaggres-
sive breast carcinoma cells. (B1, B2) Human MDA-MB-231 metastatic breast carcinoma cells. (C1, C2) Human mammary normal epithelial
cells. (D1, D2) Human WI-38 normal lung fibroblasts. In all parts of the figure, the results are of a representative experiment of n = 3.
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First, we asked if the TRKN-mutated CCL5 diverges from the WT
chemokine in its ability to associate with GAG in the Golgi. This
approach was based on our findings showing that the secretion of
WTCCL5 requires positioning of the chemokine in theGolgi (Figure 2
and [27]) and that, in the Golgi, saccharides are appended to protein
cores by glycosyltransferases, leading to formation of proteoglycans
[51]. By performing triple-dye analyses, we have shown that GFP-
CCL5(WT) was highly colocalized with GAG in the Golgi (Figure 8),
whereas the mutated GFP-CCL5(TRKN–) had a considerably re-
duced colocalization with GAG in the Golgi (Figure 9). These data
show that CCL5 is highly localized in secretion-related organelles
(Golgi) that are enriched with GAG and that this localization is
Figure 8. The localization of GFP-CCL5(WT) with GAG in the Golgi. Human MCF-7 breast tumor cells were transiently transfected by a
vector expressing GFP-CCL5(WT). The colocalization of CCL5 (green) with GAG (red), and with a Golgi marker (αmannosidase IB, purple/
blue) was determined by confocal analysis. (A) The pictures show each of the proteins alone, as well as combinations of the following:
GFP-CCL5(WT) + GAG, GFP-CCL5(WT) + Golgi, or GFP-CCL5(WT) + GAG + Golgi. The colocalization of GFP CCL5(WT) + GAG + Golgi
is demonstrated in white. (B) Higher magnification of the colocalization of GFP-CCL5(WT) with GAG and Golgi, demonstrated in bright
white. The percentage of GFP-CCL5(WT) that was colocalized with GAG and Golgi is indicated in the figure. The pictures are represen-
tatives of multiple cells analyzed in n = 3.
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associated with the expression of the positively charged 43TRKN46
motif of CCL5.
Next, we asked if GAG are required for CCL5 secretion, and to
what extent. To address this issue, we have used a highly specific
approach, in which we measured the degree of GFP-CCL5(WT)
secretion by mutated CHO cells that have substantially reduced levels
of GAG synthesis due to deficiency in xylosyltransferase, which ini-
tiates GAG biosynthesis [52]. The secretion of GFP-CCL5(WT) by
these “CHO-deficient GAG” cells (original name CHO-pgsA-745
cells) was compared to “CHO-GAG+++” cells that expressed normal
Figure 9. The localization of GFP-CCL5(TRKN–) with GAG in the Golgi. Human MCF-7 breast tumor cells were transiently transfected by a
vector expressing GFP-CCL5(TRKN–). The colocalization of CCL5 (green) with GAG (red), and with a Golgi marker (α mannosidase IB,
purple/blue) was determined by confocal analysis. (A) The pictures show each of the proteins alone, as well as combinations of the
following: GFP-CCL5(TRKN–) + GAG, GFP-CCL5(TRKN–) + Golgi, or GFP-CCL5(TRKN–) + GAG + Golgi. The colocalization of GFP-CCL5
(TRKN–) + GAG + Golgi is demonstrated in white. (B) Higher magnification of the colocalization of GFP-CCL5(TRKN–) with GAG and
Golgi, demonstrated in bright white. The percentage of GFP-CCL5(TRKN–) that was colocalized with GAG and Golgi is indicated in the
figure. The pictures are representatives of multiple cells analyzed in n = 3.
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Figure 10. The secretion of GFP-CCL5(WT) and its vesicular organization are perturbed in CHO-deficient GAG cells. CHO cells were trans-
fected by vectors expressing GFP-CCL5(WT), GFP-CCL5(TRKN–), or GFP alone (GFP), followed by determination of secretion and intracellular
organization of CCL5. The analyses were performed in cells that expressed normal GAG levels, termed herein CHO-GAG+++ cells (=CHO-
K1 cells), compared to CHO cells deficient in GAG expression, termed herein CHO-deficient GAG cells (=CHO-pgsA-745 cells). (A1, A2)
FACS analyses showing the transfection yields of GFP-CCL5(WT) and GFP-CCL5(TRKN–) in CHO-GAG+++ cells and in CHO-deficient
GAG cells. The results are of a representative experiment of n= 2-3. (B) CCL5 secretion, determined by ELISA assays performed on super-
natants of the different cell types, with antibodies against human CCL5, as described in procedure 1 in Materials and Methods. (B1) Secre-
tion of WT CCL5 in CHO-GAG+++ cells, transfected with vectors expressing GFP-CCL5(WT), GFP-CCL5(TRKN–), or GFP vector only
(=GFP). The results are of a representative experiment of n = 3. (B2) Secretion of CCL5 by CHO-GAG+++ cells and by CHO-deficient
GAG cells, transfected with GFP-CCL5(WT). The results are mean ± SD of normalized values of CCL5 secretion in n = 3. P values were
obtained from actual values of the computational analysis before normalization. (C, D) Intracellular localization of GFP-CCL5(WT) (C1, D1) and
of GFP-CCL5(TRKN–) (C2, D2) in CHO-GAG+++ cells (C1, C2) and in CHO-deficient GAG cells (D1, D2). In C and D, the results are of a
representative experiment of n = 2, with multiple cells analyzed in each experiment.
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GAG levels (original name CHO-K1 cells). Here, it is important to
indicate that 1) we ensured that the CHO-deficient GAG cells indeed
did not express GAG (data not shown) and that 2) the CHO-deficient
GAG cells do not have a general defect in secretion [53]; therefore,
they were valid for our studies.
This analysis was begun by validating that similarly to MCF-7 cells,
CHO cells that express normal levels of GAG mobilize CCL5 through
the 43TRKN46 motif. Indeed, Figure 10, A and B1, shows that, despite
similar transfection yields of GFP-CCL5(WT) and GFP-CCL5
(TRKN–) in the CHO-GAG+++ cells, the mutated GFP-CCL5
(TRKN–) chemokine was not secreted by the cells. Furthermore, the
mutated chemokine assumed a reticulate intracellular localization in
the CHO-GAG+++ cells (Figure 10C), as was the case in MCF-7 cells
(Figures 5 and 6).
Then, we compared the release of GFP-CCL5(WT) in CHO-
GAG+++ cells to its secretion by CHO-deficient GAG cells. The re-
sults in Figure 10B2 show that the control CHO-GAG+++ cells
released high levels of GFP-CCL5(WT); however, the secretion of
GFP-CCL5(WT) by CHO-deficient GAG cells was prominently
impaired, although only partly. The CHO-deficient GAG cells also
failed to release the mutated CCL5, as was the case in the other cell
lines that were investigated (data not shown).
Further analyses that were performed in the CHO-deficient GAG
cells have indicated that GAG are important not only for the secretion
of GFP-CCL5(WT) but also for its vesicular localization. Figure 10C1
shows that in CHO-GAG+++ cells, GFP-CCL5(WT) was localized in
vesicles that had a very definite punctuate distribution. In contrast, in
CHO-deficient GAG cells, the punctuate distribution of GFP-CCL5
(WT) was perturbed (Figure 10D1), and the WT chemokine was
largely localized in the ER and acquired a phenotype which was in gen-
eral similar to that of the TRKN-mutated CCL5, which was expressed
in normal, GAG-expressing cells (Figures 10C2, 5, and 6).
The roles of GAG in regulating the secretion of GFP-CCL5(WT)
was further supported by three additional methods taken to inhibit
GAG presence or synthesis in the cells. These experiments were per-
formed in the original MCF-7 breast tumor cells, in which the secre-
tion of the GFP-CCL5(WT) was analyzed with and without different
GAG inhibitory measures. We did not analyze the effects of these
measures on the mutated chemokine because it was not secreted by
the MCF-7 cells, as shown in Figure 4. In all three types of analysis,
we have ensured similar expression of the GFP-CCL5(WT) in cells
not treated, compared with cells treated by the different inhibitory
measures (see the relevant figures, as indicated herein).
The following three methods were applied to inhibit GAG func-
tions in the tumor cells: 1) We have expressed in breast tumor cells
heparanase (Figure 11), an enzyme that degrades heparane sulfate,
which is one of the GAG that bind CCL5 [44,54–56]. The results
in Figure 11A show that heparanase was expressed intracellularly in
the tumor cells, at the expected MW for the intracellularly expressed
enzyme, tagged by myc (∼65 kDa of heparanase [57] + the myc
tag). In cells expressing the enzyme intracellularly, the secretion of
GFP-CCL5(WT) was significantly inhibited, compared to control cells
transfected by vector only. However, the reduction in CCL5 secretion
after expression of heparanase was only partial (Figure 11, B and C ). 2)
In view of the importance of GAG sulfation for binding of chemokines,
including of CCL5 [33,58–60], we treated the cells with sodium chlo-
rate, a competitive inhibitor of ATP-sulfurylase that inhibits the sulfa-
tion process of GAG and is used routinely as a measure for reduction of
GAG sulfation, including in aspects related to chemokine activities
[61–63]. This treatment has also led to significant, but partial, reduc-
tion in secretion of CCL5 by the tumor cells (Figure 12A). 3) We have
deprived sulfate out of the growth medium of the cells. As shown in
Figure 12B, this measure has also led to significant inhibition of
GFP-CCL5(WT) secretion by the cells. Here again, the reduction
Figure 11. Intracellular expression of heparanase leads to reduced
secretion of GFP-CCL5(WT) by breast tumor cells. Human MCF-7
breast tumor cells were transiently transfected by a vector express-
ing GFP-CCL5(WT). In parallel, the cells were transfected with a
myc-tagged vector expressing heparanase or by a control myc-
tagged empty vector. (A) Western blot showing the expression of
heparanase in cells transfected with heparanase-containing vector
but not in cells transfected with the control vector. The analysis was
performed with antibodies againstmyc. The MW of the heparanase
is the one expected for the intracellularly expressed enzyme, tagged
by myc (∼65 kDa of heparanase + the myc tag). No signal was de-
tected in the control cells transfected with the myc-tagged vector
only because of its small MW (in the conditions used for appropriate
detection of the heparanase, the myc protein run out of the gel).
(B) FACS analysis showing the transfection yields of GFP-CCL5(WT)
in cells transfected with the heparanase vector and those transfected
with control vector. (C) CCL5 secretion to the cell supernatants de-
termined by ELISA assays with antibodies against human CCL5, as
described in procedure 1 in Materials and Methods. In all parts of
the figure, the results are of a representative experiment of n > 3.
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was partial. The combination of the sodium chlorate treatment + sulfate
deprivation did not yield additive inhibitory effects on the secretion of
GFP-CCL5(WT) by the tumor cells, and the inhibition level remained
partial (data not shown). These results indicate that the involvement of
GAG activities has reached a saturation point, with respect to their roles
in regulating CCL5 secretion.
To conclude, by taking four different inhibitory approaches, we
have shown that GAG play a significant and an important role in
mobilizing GFP-CCL5(WT) toward secretion. However, these
GAG-inhibitory measures have led to only partial reduction in secre-
tion of GFP-CCL5(WT), suggesting that other mechanisms regulate
CCL5 release as well. Our results show that GFP-CCL5(TRKN–) had
reduced localization with GAG in the Golgi and that GFP-CCL5
(WT) had an ER-like organization in GAG-deficient cells, which was
similar to the organization of the TRKN-mutated chemokine in GAG-
expressing cells. Together with supporting findings in the literature (see
Discussion), it is possible that one of the mechanisms mediating CCL5
secretion is a process involving 43TRKN46-GAG associations.
Discussion
The results of this study provide novel information on the molecular
mechanisms involved in the secretion of CCL5. They are the first to
identify a role for the 40s loop of CCL5 and for GAG in trafficking
and secretion of this chemokine. These findings contribute to our
understanding of basic processes controlling the expression of pro-
malignancy chemokines in tumor cells and may have potential
therapeutic implications, as follows:
The 43TRKN 46 Motif Is Essential for CCL5 Secretion and
for Its Inclusion in Motile Vesicles
The results of this study indicate that the secretion of a TRKN-
mutated CCL5 by breast tumor cells is prominently reduced and that
the 43TRKN46 sequence is a ubiquitous motif required for the secretion
of the chemokine by many cell types. Additional analyses that we have
performed (article in preparation) indicate that the TRKN sequence
requires the backbone of CCL5 to act as a secretion-determining motif
because it did not support the secretion of a different chemokine when
Figure 12. The secretion of GFP-CCL5(WT) by breast tumor cells is inhibited by reduced sulfation of GAG. The effects of GAG undersulfation
on the secretion of CCL5were determined in MCF-7 cells, transfected with GFP-CCL5(WT). (A) Treatment by sodium chlorate, a competitive
inhibitor of ATP-sulfurylase that inhibits the sulfation process of GAG (30mM, 48 hours). (B) The cells were exposed to sulfate deprivation by
growth in sulfate-deficient medium (48 hours). (A1, B1) FACS analyses showing the transfection yields of GFP-CCL5(WT) in control cells and
in cells in which undersulfation was induced by (A1) sodium chlorate or (B1) sulfate deprivation. (A2, B2) The secretion of CCL5 was deter-
mined by ELISA assays, performed on supernatants of control cells and of cells in which undersulfation was induced, performed with anti-
bodies against human CCL5, as described in procedure 1 in Materials and Methods. (A2) Sodium chlorate. (B2) Sulfate deprivation. In all
parts of the figure, the results are of a representative experiment of n = 3.
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it was positioned at its 40s domain (data not shown). The need for
the 40s domain of a chemokine for its secretion is supported by recent
findings showing that regions of the 40s loop regulate the sorting
of the chemokine CXCL4 (45LKNG48) into α granules in platelets
and of CXCL8 (44DSG46) into Weibel-Palade bodies in endothelial
cells [42,64].
Our confocal analyses identified a defect in the intracellular organi-
zation and in the ability of the mutated chemokine to use the appro-
priate routes on its way toward secretion. Whereas the WT chemokine
was mobilized from the ER to the post-Golgi stage and was organized
in vesicles that moved on definite microtubule tracks, the TRKN-
mutated chemokine was loosely organized in diffuse vesicles that had
random, unstructured, and limited motility in the cells.
Furthermore, our findings indicate that the 43TRKN46 motif of
CCL5 regulates the trafficking of the chemokine at two points of the
ER-to-post-Golgi path: Some of the molecules of the TRKN-mutated
chemokine could not find their way to the Golgi, and those that
did reach the Golgi could not give rise to a productive release of the
chemokine to the cell exterior. The fact that a considerable amount
of GFP-CCL5(TRKN–) molecules did exit from the ER to the Golgi
indicates that the folding of the mutated chemokine is correct; other-
wise, the ERAD process [45–47] would have led to complete arrest
of their exit from the ER.
Secretion of CCL5 Is Partly Regulated by a
GAG-Dependent Process
We have shown by four different approaches that GAG are necessary
and important for CCL5 secretion. These approaches included three
highly specific methods: one based on GAG-mutated CHO cells, the
second on the use of the enzyme heparanase that degrades heparane
sulfate, and the third on perturbation of GAG sulfation by a com-
petitive inhibitor of ATP-sulfurylase. The results of these studies
were reinforced by sulfate deprivation. Furthermore, our results with
heparanase provided a partial clue to the identity of the GAG involved
in this process, suggesting that heparane sulfate participates in the
release of CCL5 by the cells.
On the basis of the above, we propose that one of the mechanisms
mediating CCL5 secretion is based on the ability of CCL5 to “hitch-
hike” on GAG, possibly on GAG-decorated proteoglycans, that
make their way to the cell membrane or to the cell exterior. Support-
ing this mechanism are two recent studies, one by Meen et al. [65]
that suggested that a proteoglycan-mediated process was involved in
the secretion of the chemokine CXCL1 by endothelial cells and the
second on FGF-2, showing that extracellular heparane sulfate proteo-
glycans formed a molecular trap that translocated the protein across
the plasma membrane [66].
It is interesting to note that all four measures that were taken in our
study to reduce GAG activities/expression were in good agreement
with each other, all yielding similar inhibition levels of CCL5 secre-
tion, between 40% and 60%. It is possible that the presence or
synthesis of GAG was not completely shut down by any of these
measures; however, as indicated in the Results section, when sulfate
deprivation was combined with sodium chlorate, there was no additive
inhibitory effect, and the inhibition of CCL5 secretion remained
partial (data not shown).
Therefore, it is very likely that the partial reduction in CCL5 secre-
tion, which was obtained by the different measures of GAG inhibition,
actually reflects the existence of alternative mechanisms that are in-
volved in CCL5 secretion. Because the absence of the 43TRKN46 motif
has led to complete inhibition of CCL5 secretion whereas the degree
of GAG involvement in CCL5 secretion was only partial, such addi-
tional mechanisms possibly also regulate the secretion of CCL5 in a
43TRKN46-dependent manner. On the basis of the literature, we spec-
ulate that one such additional mechanism may be based on CCR1
and CCR3, at least in breast tumor cells, because these cells express
such receptors [7,19]. This possibility is supported by the fact that
the 44RKNR47 sequence mediates the binding of CCL5 to CCR1
and CCR3 [43,44]. These findings stand in the basis of our plans to
investigate whether CCR1 and CCR3 regulate the release of CCL5 in
breast tumor cells.
Taking our novel findings a step further and considering them with
additional results provided in our study and in the literature, it is logical
to assume that the secretion of CCL5 by breast tumor cells is regulated
by associations formed through its 43TRKN46 motif with GAG. This
possibility is supported by the following observations: 1) In contrast to
WT CCL5 that had a definite colocalization with GAG in the Golgi,
the TRKN-mutated chemokine had much lower propensity to such
colocalization. These findings indicate that the existence of the posi-
tively charged 43TRKN46 motif of CCL5 is associated with the locali-
zation of the chemokine in GAG-enriched secretion-related organelles
(Golgi) and supports the role of 43TRKN46-GAG associations in the
secretion of CCL5. 2) Our confocal analyses have shown that WT
CCL5 acquired a reticulate localization phenotype, which is typical
of ER, in CHO-deficient GAG cells, similar to the one detected for
the TRKN-mutated chemokine in normal GAG expressing cells. This
observation suggests that the organization of CCL5 in the Golgi is
mediated through the 43TRKN46 motif. 3) Our secretion-regulating
43TRKN46 sequence carries two of the three basic residues found in
the 44RKNR47 motif, that is essential for CCL5 binding to GAG
[33,43,44,60]. 4) Being a CC chemokine, CCL5 was found to be ex-
pressed in supernatants of human immunodeficiency virus–specific cyto-
lytic T cells in complexes with proteoglycans [50]. Our study suggests
that the reason forCCL5 associationwith proteoglycans in the extracellular
milieu of those cells is that the chemokine associated with them intra-
cellularly on its path toward secretion and that this process involved
a 43TRKN46-GAG–mediated mechanism.
From the therapeutic point of view, the identification of the compo-
nents that regulate the secretion of CCL5 may have potential implica-
tions, as they may pave the way toward the future design of modalities
that inhibit 43TRKN46-mediated or GAG-mediated mechanisms, lead-
ing thereafter to reduced release of CCL5 by breast tumor cells. More-
over, the fact that the 43TRKN46 motif is required for the secretion of
CCL5 bymany cell types (Figure 7) suggests that the different measures
taken to reduce the 43TRKN46-mediated process of CCL5 secretion
may inhibit the release of the chemokine also by tumor-promoting host
cells that are found at the tumor microenvironment, like leukocytes
or mesenchymal stem cells, that contribute to tumor growth through
CCL5 release [13,24].
Although such an approach may lead to inhibition of CCL5 secre-
tion also at inflammatory sites, it is not expected to impose a threat
on the immune integrity of the host because the immune activities of
CCL5 are backed up by other chemokines [67,68]. One additional
aspect of inhibitory modalities that target the 43TRKN46-mediated
or GAG-mediated mechanism is the question whether they would
lead also to reduced secretion of other chemokines or to interference
with their binding to GAG in other cell types. The interactions
of many chemokines with GAG are mediated by basic amino acids
of the chemokines and negative charges of the GAG molecules.
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However, the different chemokines diverge in the sequences through
which they bind to GAG and in the positions of such domains in
the chemokine sequence. Hence, it is possible that the secretion of
other chemokines would not be affected when the 43TRKN46-mediated
or GAG-mediated trafficking of CCL5 is targeted and inhibited.
To conclude, our study has provided novel findings on the regula-
tory processes involved in the secretion of CCL5 by breast tumor cells
and are the first to identify the important roles played by the 40s loop
of CCL5 and of GAG in the secretion of this chemokine. In our future
studies, we will aim at targeting the 43TRKN46-mediated or GAG-
mediated mechanisms that lead CCL5 toward secretion and will de-
termine the effects of such inhibitory measures on the malignancy
phenotype of breast tumor cells.
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Figure W1. Intracellular distribution of HA-CCL5(WT). HumanMCF-7
breast tumor cells were transiently transfected by a vector express-
ing HA-CCL5(WT). Confocal analysis has shown vesicular distribution
and Golgi localization of the chemokine, similarly to the intracellular
phenotype obtained for GFP-CCL5(WT) (Figs. 1, 6, and 8) and to
endogenous CCL5 in breast tumor cells [27].
Video W1. Vesicles containing GFP-CCL5(WT) have dynamic motil-
ity in MCF-7 human breast tumor cells. The control empty vector
expressing GFP had a diffuse nonorganized distribution in the cells
(data not shown).
Video W2. After short BFA treatment of MCF-7 cells, the Golgi
collapsed but vesicles containing GFP-CCL5(WT) were still apparent
close to the cell periphery, indicating that they have reached the
post-Golgi stage.
Video W3. Vesicles containing GFP-CCL5(WT) moved along direc-
tional and structured tracks in MCF-7 human breast tumor cells.
Video W5. The movie follows the same cells that were shown in
Video W4, but now after nocodazole treatment, demonstrating
reduced motility of CCL5-containing vesicles, and their decelerated
movement along well defined paths.
Figure W2. Further evidence to prominent reduction in secretion of GFP-CCL5(TRKN–) compared to GFP-CCL5(WT) by breast tumor
cells. Human MCF-7 breast tumor cells were transiently transfected by vectors expressing GFP-CCL5(WT) or GFP-CCL5(TRKN–), fol-
lowed by determination of chemokine expression in cell supernatants. (A) ELISAs with mAb to GFP and polyclonal detecting antibodies
to CCL5 (“Procedure 3” in “Materials and methods”). (B) ELISAs with polyclonal coating antibodies to CCL5 and polyclonal detecting
antibodies to CCL5 (“Procedure 4” in “Materials and methods”).
Video W4.MCF-7 cells expressing GFP-CCL5(WT) before treatment
with nocodazole showing dynamic motility of vesicles. The same
cells after nocodazole treatment are shown in Video W5.
Video W6. In transfected MCF-7 cells, GFP-CCL5(TRKN–) is less
organized in vesicles than GFP-CCL5(WT) (Video W1), and those
vesicles that contain GFP-CCL5(TRKN–) have nondirectional and
limited motility.
